Review anchor
NAD-dependent protein deacetylase sirtuin-3, mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
NAD-dependent protein deacetylase sirtuin-3, mitochondrial
CHEMBL4461
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats NAD-dependent protein deacetylase sirtuin-3, mitochondrial as ChEMBL target CHEMBL4461, mapped to UniProt Q9NTG7. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4461
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9NTG7
NAD-dependent protein deacetylase sirtuin-3, mitochondrial
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why NAD-dependent protein deacetylase sirtuin-3, mitochondrial matters
NAD-dependent protein deacetylase sirtuin-3, mitochondrial is reviewed as NAD-dependent protein deacetylase sirtuin-3, mitochondrial (UniProt Q9NTG7); the current evidence base includes 3 approved drugs, 1022 compounds, and 272 assays, with lead potency reaching pChEMBL 8.5.
Protein context
NAD-dependent protein deacetylase sirtuin-3, mitochondrial
NAD-dependent protein deacetylase sirtuin-3, mitochondrial Sequence length is 399 aa.
Review this target as NAD-dependent protein deacetylase sirtuin-3, mitochondrial, mapped to UniProt Q9NTG7. Sequence length is 399 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9NTG7
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 1022 compounds, and 272 assays for this target. The dominant activity type is IC50. CHEMBL2332041 is the current potency anchor at pChEMBL 8.5.
Use CHEMBL2332041 as the tractability anchor when discussing potency (pChEMBL 8.5).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 8.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why NAD-dependent protein deacetylase sirtuin-3, mitochondrial matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9NTG7, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1022
Total Compounds
272
Total Assays
3
Approved Drugs
IC50: 511.0, KI: 22.0, EC50: 37.0, KD: 33.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2332041
|
8.5 | IC50 | — |
|
|
No preferred name
CHEMBL2332039
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL2332037
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL5614132
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL2338810
|
8.1 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CAFFEINE
CHEMBL113
|
1948 |
Source Header